Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.27 USD
Change Today +0.02 / 1.60%
Volume 1.5K
PDII On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

pdi inc (PDII) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/29/14 - $5.05
52 Week Low
05/1/15 - $1.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PDI INC (PDII)

pdi inc (PDII) Related Bloomberg News

View More Bloomberg News

pdi inc (PDII) Related Businessweek News

No Related Businessweek News Found

pdi inc (PDII) Details

PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. It operates in two segments, Commercial Services and Interpace Diagnostics. The Commercial Services segment offers outsourced sales teams that target healthcare providers, providing a range of complementary sales support services designed to achieve its customers' strategic and financial product objectives. This segment offers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It also provides other promotional services, including clinical educator, teledetailing, and full product commercialization services. This segment’s services include product distribution, personal and non-personal product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. The Interpace Diagnostics segment focuses on developing and commercializing molecular diagnostic tests for physicians and patients with diagnostic options for detecting genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. This segment offers PancraGen, a diagnostic test designed for determining risk of malignancy in pancreatic cysts; and ThyGenX, a next-generation sequencing test designed to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. It also has three diagnostic tests in late stage development that are designed to detect genetic alterations that are associated with gastrointestinal cancers; and one diagnostic test in late stage development that is designed to detect genetic alterations that are associated with endocrine cancers. PDI, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

775 Employees
Last Reported Date: 03/5/15
Founded in 1986

pdi inc (PDII) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $736.5K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $86.2K
President of Sales Services
Total Annual Compensation: $386.3K
Compensation as of Fiscal Year 2014.

pdi inc (PDII) Key Developments

PDI, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Year 2015

PDI, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue, net of $38,319,000 against $31,832,000 a year ago. Operating loss was $2,882,000 against $414,000 a year ago. Loss from continuing operations before income tax was $3,816,000 against $431,000 a year ago. Loss from continuing operations was $3,743,000 or $0.26 per basic and diluted share against $497,000 or $0.11 per diluted share a year ago. Net loss was $3,868,000 or $0.26 per basic and diluted share against $1,612,000 or $0.11 per basic and diluted share a year ago. Net cash used in operations was $5,617,000 against $6,463,000 a year ago. Adjusted operating loss was $2,012,000 compared with $414,000 a year ago. For the year 2015, the company expects total net revenue of $136 million to $140 million including: Commercial Services net revenue of $123 million to $126 million, representing approximately 3% to 6% growth over the prior year; and reiterating Interpace Diagnostics net revenue of $13 million and $14 million.  Previously the Company's guidance was $131 to $140 million in net revenue: Commercial Services revenue of $121 million to $125 million; and Interpace Diagnostics revenue of $13 million to $14 million. Adjusted operating loss (as defined below) of $17 million to $19 million.

PDI, Inc. Proposes to Amend the Certificate of Incorporation

PDI, Inc. proposed to amend the company's certificate of incorporation to increase the number of authorized shares of common stock from 40,000,000 to 100,000,000 at the AGM to be held on June 03, 2015.

Prolias Technologies Files Suit against PDI Inc

Prolias Technologies, Inc. has filed suit against PDI Inc. PDI is alleged to have engaged breach of contract, breach of covenant of good faith and fair dealing, intentional interference with contract, and breach of fiduciary duty. The complaint was filed in Superior Court of New Jersey for the County of Morris (Docket number 899/15). The complaint alleges that PDI breached a Joint Venture Agreement with Prolias to validate, commercialize and ultimately monetize 'Thymira', a microRNA based thyroid cancer test. According to the complaint, PDI breached its obligations under the Agreement and committed a variety of torts by, among other wrongs, failing to effectively and timely validate "Thymira", buying a competitor and developing its competitive product in lieu of 'Thymira', interfering with the license agreement between Cornell and the Prolias Technologies, and, upon information and belief, attempting to purchase the license agreement from Cornell directly and to the exclusion of the Prolias Technologies. The complaint further alleges that PDI practically usurped the name 'Thymira' from Prolias by naming its competitive product 'Thyramir'.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDII:US $1.27 USD +0.02

PDII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Quest Diagnostics Inc $79.60 USD +5.72
Quintiles Transnational Holdings Inc $69.70 USD +0.99
Veracyte Inc $10.69 USD -0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation PDII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDI INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at